Stefanie Wculek profile picture

Stefanie Wculek

Professor at IRB Barcelona

IRB Barcelona
Country flagSpain

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Positions (1)

Publisher
source

Stefanie Wculek

University Name
.

IRB Barcelona

IRB Barcelona is recruiting two Postdoctoral Fellows in the Innate Immune Biology laboratory led by Dr. Stefanie Wculek . The projects focus on dendritic cells and neutrophils , with a strong emphasis on immunometabolism , aging , obesity , and metabolic disease . One project will investigate the tissue-specific biology of dendritic cells in aging, including context-dependent adaptations in young and aging-associated obese tissues and the molecular mechanisms behind these changes. The second project will study the immunometabolism of neutrophils in health, obesity, and metabolic disease, aiming to uncover mechanistic links between functional and metabolic alterations in mouse and human neutrophils. Successful candidates are expected to work independently and analyze/interpret transcriptomic, proteomic, epigenetic, and metabolomic datasets in collaboration with the bioinformatics unit. The role also involves advanced experimental work with mouse models , primary tissue culture, human samples, multicolor flow cytometry, cell sorting, multiplex microscopy, spatial tissue analysis, epigenetic analyses, and metabolic assays. Applicants should hold a PhD in biomedicine or biosciences (ideally completed within the last 2 years). Experience in dendritic cells, neutrophils, innate immunity, immunometabolism, aging, obesity, or metabolic disease is highly relevant. Bioinformatic and multi-omics experience, as well as work with primary human cells/tissues, are especially valued. Strong English communication, teamwork, motivation, and organizational skills are required. The positions are full-time postdoctoral contracts at IRB Barcelona. One post is co-funded by the European Research Council project MyTissue (Grant Agreement 101117470), and the other is funded by MICIU/AEI under action CNS2025-165793. The institute offers a competitive salary, Spanish Social Security coverage, training and career development, and relocation/visa assistance. Deadline: 2026-06-25. Applicants should submit a CV, motivation letter, and relevant experience through the IRB Barcelona recruitment portal.

5 months ago

Articles (1)

The ability of conventional type-1 dendritic cells (cDC1) to cross-present tumor antigens to CD8 + T cells is critical for the induction of antitumor CTLs. Mice that are constitutively deficient in cDC1 cells have been reported to fail to respond to immunotherapy strategies based on checkpoint inhibitors. However, further work is needed to clarify the precise time during immunotherapy treatment that cDC1 cells are required for the beneficial effect of treatment. Here, we used a refined XCR1-DTR-Venus transgenic mouse model to acutely deplete cDC1 cells and trace their behavior using intravital microscopy. Diphtheria toxin–mediated cDC1 depletion prior to immunotherapy treatment with anti–PD-1 and/or anti-CD137 immunostimulatory mAbs completely ablated antitumor efficacy. The efficacy of adoptive T-cell therapy was also hampered by prior cDC1 depletion. After the onset of immunotherapy treatment, depletion of cDC1s only moderately reduced the therapeutic efficacy of anti–PD-1 and anti-CD137 mAbs. Intravital microscopy of liver-engrafted tumors revealed changes in the intratumoral behavior of cDC1 cells in mice receiving immunotherapy, and treatment with diphtheria toxin to deplete cDC1s impaired tumor T-cell infiltration and function. These results reveal that the functional integrity of the cDC1 compartment is required at the onset of various immunotherapies to successfully treat established tumors. Significance: These findings reveal the intratumoral behavior of cDC1 dendritic cells in transgenic mouse models and demonstrate that the efficacy of immunotherapy regimens is precluded by elimination of these cells.

Year:

2025

Collaborators (5)

Pedro Berraondo

-

SPAIN
View details

Ignacio Melero

Kidani Professor of Cancer Immuno-Therapeutics

University of Oxford

UNITED KINGDOM
View details

Alvaro Teijeira

Centro de Investigación Médica Aplicada, Universidad de Navarra

SPAIN
View details

Vladislav V. Verkhusha

University of Helsinki

FINLAND
View details

Carlos E de Andrea

-

SPAIN
View details